Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Effects of Bile Acids After Gastric Bypass
NCT06925997Phase 1Recruiting
- Sponsor
- Copenhagen University Hospital - Hvidovre
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of colesevelam in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Copenhagen University Hospital - Hvidovre. Primary endpoints: Glucose at 8 weeks and Fibroblast Growth Factor-19 at 8 weeks. Started May 2024; status: recruiting.
02
Drugs
colesevelam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06925997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925997.